917389-34-5

Basic information

• Product Name: (R)-methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetate
• Synonyms: (R)-methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetate
• CAS NO: 917389-34-5
• Molecular Weight: 586.586
• Mol File: 917389-34-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (R)-methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetate(917389-34-5)
• EPA Substance Registry System: (R)-methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetate(917389-34-5)

Safety Data

• Hazardous Substances Data: 917389-34-5(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 791116-51-3 (+/-)-{8-fluoro-2-[4-(3-methoxyphenyl)-piperazin-1-yl]-3-[2-methoxy-5-trifluoromethyl-phenyl]-3,4-dihydro-quinazolin-4-yl}acetic acid 
• 65896-11-9 2-bromo-6-fluoroaniline 
• 16588-75-3 2-methoxy-5-trifluoromethylphenyl isocyanate 
• 917389-35-6 [(R)-8-fluoro-2-[4-(3-methoxy-phenyl)-piperazin-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-3,4-dihydro-quinazolin-4-yl]-acetic acid methyl ester (2R,3R)-2,3-bis-(4-methyl-benzoyloxy)-succinic acid salt 
• 917389-21-0 methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxo-1,2,3,4-tetrahydroquinazolin-4-yl)acetate 
• 917389-23-2 3-(2-bromo-6-fluorophenyl)-1-[2-methoxy-5-(trifluoromethyl)phenyl]urea 
• 917389-24-3 N-(2-fluorophenyl)-N'-[2-methoxy-5-(trifluoromethyl)phenyl]urea 
• 348-54-9 2-Fluoroaniline 
• 917389-37-8 (R)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid 
• 791117-40-3 methyl 2-[8-fluoro-3-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-yl] acetate 
• 917389-26-5 methyl-(E)-3-(3-fluoro-2-(3-(2-methoxy-5-(trifluoromethyl)phenyl)ureido)phenyl)acrylate 
• 349-65-5 2-Methoxy-5-trifluoromethyl-aniline 

Downstream Products

• 917389-35-6 [(R)-8-fluoro-2-[4-(3-methoxy-phenyl)-piperazin-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-3,4-dihydro-quinazolin-4-yl]-acetic acid methyl ester (2R,3R)-2,3-bis-(4-methyl-benzoyloxy)-succinic acid salt 
• 917389-37-8 (R)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid 
• 917389-32-3 (S)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)-phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid 
• 791117-40-3 methyl 2-[8-fluoro-3-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-yl] acetate 
• 791116-51-3 (+/-)-{8-fluoro-2-[4-(3-methoxyphenyl)-piperazin-1-yl]-3-[2-methoxy-5-trifluoromethyl-phenyl]-3,4-dihydro-quinazolin-4-yl}acetic acid 

Relevant articles and documents

Asymmetric synthesis of letermovir using a novel phase-Transfer-catalyzed aza-michael reaction

The development of a concise asymmetric synthesis of the antiviral development candidate letermovir is reported, proceeding in 60% yield over a total of seven steps from commercially available materials. Key to the effectiveness of this process is a nove

Combining traditional 2D and modern physical organic-derived descriptors to predict enhanced enantioselectivity for the key aza-Michael conjugate addition in the synthesis of Prevymis (letermovir)

Quantitative structure-activity relationships have an extensive history for optimizing drug candidates, yet they have only recently been applied in reaction development. In this report, the predictive power of multivariate parameterization has been explored toward the optimization of a catalyst promoting an aza-Michael conjugate addition for the asymmetric synthesis of letermovir. A hybrid approach combining 2D QSAR and modern 3D physical organic parameters performed better than either approach in isolation. Using these predictive models, a series of new catalysts were identified, which catalyzed the reaction to provide the desired product in improved enantioselectivity relative to the parent catalyst.

METHOD FOR PRODUCING DIHYDROQUINAZOLINES

The present invention relates to a method for producing dihydroquinazolines of formula (I), which are used to manufacture medicaments.